文献速递哮喘慢阻肺

一般人群中慢性气道疾病的2型炎症与肺功能下降

Type-2 inflammation and lung function decline in chronic airway disease in the general population.
PubMed 文献 · Thorax · 2024-03-15

研究基于哥本哈根一般人群队列,纳入有血嗜酸性粒细胞(BE)和呼出气一氧化氮(FeNO)测量的成人,评估既往10年FEV1下降。结果显示BE和FeNO升高与FEV1加速下降相关,该关联在哮喘样表型中最明显。

要点

  • BE每升高100 cells/μL,FEV1年下降增加1.0 mL/年(95%CI 0.6-1.4)。
  • FeNO每升高10 ppb,FEV1年下降增加3.2 mL/年(95%CI 2.0-4.5)。
  • BE≥300 cells/μL且FeNO≥20 ppb者FEV1下降最快,哮喘样表型中尤甚。

核心结论

  • BE和FeNO升高的2型炎症与一般人群慢性气道疾病患者FEV1加速下降相关。
  • 该关联在哮喘样表型中最为明显。

研究设计与样本

  • 研究纳入哥本哈根一般人群队列成人,BE测量N=15 605,FeNO测量N=2 583。
  • 基于随访时支气管舒张前后肺功能、吸烟史和哮喘状态分组,评估既往10年FEV1下降。

主要发现

  • FEV1年下降随BE每100 cells/μL升高增加1.0 mL/年(95%CI 0.6-1.4,p<0.0001)。
  • FEV1年下降随FeNO每10 ppb升高增加3.2 mL/年(95%CI 2.0-4.5,p<0.0001)。
  • 调整后FEV1年下降在BE<300 cells/μL且FeNO<20 ppb者为18 mL/年(95%CI 17-20),BE≥300 cells/μL或FeNO≥20 ppb者为22 mL/年(95%CI 19-25),两者均高者为27 mL/年(95%CI 21-33)(趋势p<0.0001)。
  • 在AR组,上述三组FEV1年下降分别为24(95%CI 19-29)、33(95%CI 25-40)、44(95%CI 31-56)mL/年(p=0.002)。
  • 在APO组分别为26(95%CI 14-37)、36(95%CI 12-60)、56(95%CI 24-89)mL/年(p=0.07);COPD组分别为32(95%CI 27-36)、31(95%CI 24-38)、44(95%CI 24-65)mL/年(p=0.46);NAL组分别为27(95%CI 21-33)、35(95%CI 26-45)、37(95%CI 25-49)mL/年(p=0.10)。

临床怎么用

  • 在慢性气道疾病患者中,可结合BE和FeNO评估2型炎症,识别FEV1加速下降风险较高的个体。
  • BE≥300 cells/μL且FeNO≥20 ppb提示肺功能下降风险更高,尤其在哮喘样表型者中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear if type-2 inflammation is associated with accelerated lung function decline in individuals with asthma and chronic obstructive pulmonary disease (COPD). We tested the hypothesis that type-2 inflammation indicated by elevated blood eosinophils (BE) and fraction of exhaled nitric oxide (FeNO) is associated with accelerated lung function decline in the general population. METHODS: We included adults from the Copenhagen General Population Study with measurements of BE (N=15 605) and FeNO (N=2583) from a follow-up examination and assessed forced expiratory volume in 1 s (FEV1) decline in the preceding 10 years. Based on pre- and post-bronchodilator lung function, smoking history and asthma at follow-up examination, participants were assigned as not having airway disease, asthma with full reversibility (AR), asthma with persistent obstruction (APO), COPD, and not classifiable airflow limitation (NAL). RESULTS: FEV1 decline in mL/year increased with 1.0 (95% CI 0.6 to 1.4, p<0.0001) per 100 cells/µL higher BE and with 3.2 (95% CI 2.0 to 4.5, p<0.0001) per 10 ppb higher FeNO. Adjusted FEV1 decline in mL/year was 18 (95% CI 17 to 20) in those with BE<300 cells/µL and FeNO<20 ppb, 22 (19-25) in BE≥300 cells/µL or FeNO≥20 ppb, and 27 (21-33) in those with BE≥300 cells/µL and FeNO≥20 ppb (p for trend<0.0001). Corresponding FEV1 declines were 24 (19-29), 33 (25-40) and 44 (31-56) in AR (0.002), 26 (14-37), 36 (12-60) and 56 (24-89) in APO (0.07), 32 (27-36), 31 (24-38) and 44 (24-65) in COPD (0.46), and 27 (21-33), 35 (26-45), and 37 (25-49) in NAL (0.10), respectively. CONCLUSIONS: Type-2 inflammation indicated by elevated BE and FeNO is associated with accelerated FEV1 decline in individuals with chronic airway disease in the general population, and this association was most pronounced in an asthma-like phenotype.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Çolak Y, Afzal S, Marott JL, et al. Type-2 inflammation and lung function decline in chronic airway disease in the general population. Thorax. 2024. PMID: 38195642. doi:10.1136/thorax-2023-220972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。